전체메뉴
검색
Article Search

JMB Journal of Microbiolog and Biotechnology

QR Code QR Code

Articles Service

Supplementary
Share this article on :
Metrics

Related articles in JMB

More Related Articles

Review

Molecular and Cellular Microbiology (MCM)  |  Infection and Immunity

Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses

Kyun-Do Kim† , Insu Hwang† , Keun Bon Ku† , Sumin Lee, Seong-Jun Kim*, and Chonsaeng Kim*

Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea

Correspondence to:
Seong-Jun Kim, 
sekim@krict.re.kr
Chonsaeng Kim, 
chonskim@krict.re.kr
Received: June 3, 2020; Revised: June 15, 2020; Accepted: June 15, 2020

J. Microbiol. Biotechnol. 2020; 30(8): 1109-1115

Published August 28, 2020 https://doi.org/10.4014/jmb.2006.06006

Copyright © The Korean Society for Microbiology and Biotechnology.

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading globally, and the WHO has declared this outbreak a pandemic. Vaccines are an effective way to prevent the rapid spread of COVID-19. Furthermore, the immune response against SARS-CoV-2 infection needs to be understood for the development of an efficient and safe vaccine. Here, we review the current understanding of vaccine targets and the status of vaccine development for COVID-19. We also describe host immune responses to highly pathogenic human coronaviruses in terms of innate and adaptive immunities.

Keywords

COVID-19, SARS-CoV-2, Coronavirus, vaccine, immune response

Graphical Abstract

References

  1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273.
  2. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. 2016. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15: 327-347.
    Pubmed PMC
  3. Cheng VC, Lau SK, Woo PC, Yuen KY. 2007. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 20: 660-694.
    Pubmed PMC
  4. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. 2015. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28: 465-522.
    Pubmed PMC
  5. Lee JY, Bae S, Myoung J. 2019. Middle East respiratory syndrome Coronavirus-encoded accessory proteins impair MDA5-and TBK1-mediated activation of NF-κB. J. Microbiol. Biotechnol. 29: 1316-1323.
    Pubmed
  6. Gralinski LE, Baric RS. 2015. Molecular pathology of emerging coronavirus infections. J. Pathol. 235: 185-195.
    Pubmed PMC
  7. Velavan TP, Meyer CG. 2020. The COVID-19 epidemic. Trop. Med. Int. Health 25: 278-280.
    Pubmed PMC
  8. Lake MA. 2020. What we know so far: COVID-19 current clinical knowledge and research. Clin. Med (Lond). 20: 124-127.
    Pubmed PMC
  9. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. 2020. Clinical characteristics of Coronavirus disease 2019 in China. N. Engl. J. Med. 382: 1708-1720.
    Pubmed PMC
  10. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. 2020. Early transmission dynamics in Wuhan, China, of novel CoronavirusInfected pneumonia. N. Engl. J. Med. 382: 1199-1207.
    Pubmed PMC
  11. Prompetchara E, Ketloy C, Palaga T. 2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol. 38: 1-9.
  12. Cucinotta D, Vanelli M. 2020. WHO declares COVID-19 a pandemic. Acta Biomed. 91: 157-160.
  13. Lu S. 2020. Timely development of vaccines against SARS-CoV-2. Emerg. Microbes Infect. 9: 542-544.
    Pubmed PMC
  14. Lee J, Bae S, Myoung J. 2019. Generation of full-length infectious cDNA clones of middle east respiratory syndrome coronavirus. J. Microbiol. Biotechnol. 29: 999-1007.
    Pubmed
  15. Jiang S, He Y, Liu S. 2005. SARS vaccine development. Emerg. Infect. Dis. 11: 1016-1020.
    Pubmed PMC
  16. Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. 2019. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. Front. Microbiol. 10: 1781.
    Pubmed PMC
  17. Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, et al. 2007. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir. Ther. 12: 1107-1113.
  18. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, et al. 2008. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26: 6338-6343.
    Pubmed PMC
  19. Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. 2019. Safety and immunogenicity of an antiMiddle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect. Dis. 19: 1013-1022.
  20. Ahmed SF, Quadeer AA, McKay MR. 2020. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12: 254.
    Pubmed PMC
  21. Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. 2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum. Vaccin. Immunother. 16: 12321238.
    Pubmed PMC
  22. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding. Lancet 395: 565-574.
  23. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367: 1260-1263.
    Pubmed PMC
  24. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367: 1444-1448.
    Pubmed PMC
  25. Zhou Y, Jiang S, Du L. 2018. Prospects for a MERS-CoV spike vaccine. Expert Rev. Vaccines 17: 677-686.
    Pubmed PMC
  26. Koyama S, Ishii KJ, Coban C, Akira S. 2008. Innate immune response to viral infection. Cytokine 43: 336-341.
    Pubmed
  27. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. 2011. Pattern recognition receptors and the innate immune response to viral infection. Viruses 3: 920-940.
    Pubmed PMC
  28. Teijaro JR. 2016. Type I interferons in viral control and immune regulation. Curr. Opin. Virol. 16: 31-40.
    Pubmed PMC
  29. Jensen S, Thomsen AR. 2012. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J. Virol. 86: 2900-2910.
    Pubmed PMC
  30. He L, Ding Y, Zhang Q, Che X, He Y, Shen H, et al. 2006. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoVinfected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 210: 288-297.
    Pubmed PMC
  31. Perlman S, Dandekar AA. 2005. Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 5: 917927.
    Pubmed PMC
  32. Zumla A, Hui DS, Perlman S. 2015. Middle East respiratory syndrome. Lancet 386: 995-1007.
  33. Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, Onderwater JJ, van der Meulen J, Koerten HK, et al. 2006. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J. Virol. 80: 59275940.
    Pubmed PMC
  34. Blanchard E, Roingeard P. 2015. Virus-induced double-membrane vesicles. Cell. Microbiol. 17: 45-50.
    Pubmed PMC
  35. Haller O, Kochs G. 2002. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic 3: 710-717.
    Pubmed
  36. Sen GC. 2001. Viruses and interferons. Annu. Rev. Microbiol. 55: 255-281.
    Pubmed
  37. Kurche JS, Haluszczak C, McWilliams JA, Sanchez PJ, Kedl RM. 2012. Type I IFN-dependent T cell activation is mediated by IFNdependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression. J. Immunol. 188: 585-593.
    Pubmed PMC
  38. Lee JY, Kim SJ, Myoung J. 2019. Middle East respiratory syndrome Coronavirus-Encoded ORF8b inhibits RIG-I-Like receptors in a differential mechanism. J. Microbiol. Biotechnol. 29: 2014-2021.
    Pubmed
  39. Lee JY, Bae S, Myoung J. 2019. Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-beta promoter activation: its implication for vaccine design. J. Microbiol. 57: 803-811.
    Pubmed PMC
  40. Lokugamage KG, Schindewolf C, Menachery VD. 2020. SARS-CoV-2 sensitive to type I interferon pretreatment. bioRxiv 2020.2003.2007.982264.
  41. Team CC-R. 2020. Severe outcomes among patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12March 16, 2020. MMWR Morb Mortal Wkly Rep. 69: 343-346.
    Pubmed
  42. Shaw AC, Goldstein DR, Montgomery RR. 2013. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13: 875-887.
    Pubmed PMC
  43. Li T, Qiu Z, Zhang L, Han Y, He W, Liu Z, et al. 2004. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J. Infect. Dis. 189: 648-651.
    Pubmed PMC
  44. Xie J, Fan HW, Li TS, Qiu ZF, Han Y. 2006. [Dynamic changes of T lymphocyte subsets in the long-term follow-up of severe acute respiratory syndrome patients]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 28: 253-255.
  45. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. 2020. Clinical progression of patients with COVID-19 in Shanghai, China. J. Infect. 80: e1-e6.
    Pubmed PMC
  46. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. 2020. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 71: 762-768.
    Pubmed PMC
  47. Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. 2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell. Mol. Immunol. 17: 541-543.
    Pubmed PMC
  48. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. 2016. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 19: 181-193.
    Pubmed PMC
  49. Snell LM, Osokine I, Yamada DH, De la Fuente JR, Elsaesser HJ, Brooks DG. 2016. Overcoming CD4 Th1 cell fate restrictions to sustain antiviral CD8 T cells and control persistent virus infection. Cell. Rep. 16: 3286-3296.
    Pubmed PMC
  50. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. 2004. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 136: 95-103.
    Pubmed PMC
  51. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. 2018. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 104: 8-13.
    Pubmed PMC
  52. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506.
  53. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, et al. 2015. Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. USA 112: 4719-4724.
    Pubmed PMC
  54. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. 2020. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med. 26: 453-455.
    Pubmed PMC
  55. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. 2012. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76: 16-32.
    Pubmed PMC
  56. Newton AH, Cardani A, Braciale TJ. 2016. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin. Immunopathol. 38: 471-482.
    Pubmed PMC
  57. Ababneh M, Alrwashdeh M, Khalifeh M. 2019. Recombinant adenoviral vaccine encoding the spike 1 subunit of the Middle East Respiratory Syndrome Coronavirus elicits strong humoral and cellular immune responses in mice. Vet. World 12: 1554-1562.
    Pubmed PMC
  58. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. 2020. Coronavirus infections and immune responses. J. Med. Virol. 92: 424-432.
    Pubmed PMC
  59. Li G, Chen X, Xu A. 2003. Profile of specific antibodies to the SARS-associated coronavirus. N. Engl. J. Med. 349: 508-509.
    Pubmed
  60. Cheng M, Chan CW, Cheung RC, Bikkavilli RK, Zhao Q, Au SW, et al. 2005. Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11. Biochem. Biophys. Res. Commun. 338: 1654-1660.
    Pubmed PMC
  61. Zhou G, Zhao Q. 2020. Perspectives on therapeutic neutralizing antibodies against the novel Coronavirus SARS-CoV-2. Int. J. Biol. Sci. 16: 1718-1723.
    Pubmed PMC
  62. Mubarak A, Alturaiki W, Hemida MG. 2019. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J. Immunol. Res. 2019: 6491738.
    Pubmed PMC
  63. Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, et al. 2014. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32: 3169-3174.
    Pubmed PMC
  64. Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M, et al. 2016. Persistence of antibodies against Middle East Respiratory Syndrome Coronavirus. Emerg. Infect. Dis. 22: 1824-1826.
    Pubmed PMC
  65. Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, et al. 2006. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J. Infect. Dis. 193: 792-795.
    Pubmed PMC
  66. Tang F, Quan Y, Xin ZT, Wrammert J, Ma MJ, Lv H, et al. 2011. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J. Immunol. 186: 7264-7268.
    Pubmed
  67. Zhang B, Zhou X, Zhu C, Feng F, Qiu Y, Feng J, et al. 2020. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. Front. Mol. Biosci. 7: 157.
    Pubmed PMC
  68. Haveri A, Smura T, Kuivanen S, Osterlund P, Hepojoki J, Ikonen N, et al. 2020. Serological and molecular findings during SARSCoV2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 25: 2000266.
    Pubmed PMC
  69. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. 2019. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 4: e123158.
    Pubmed PMC